Herpes zoster triggered by ChAdOx1 nCoV-19 coronavirus vaccine (recombinant)

被引：0
|
作者：
George, Neethu Mary [1 ]
机构：
[1] Mar Sleeva Med Palai, Kottayam, Kerala, India
来源：
NATIONAL MEDICAL JOURNAL OF INDIA | 2024年 / 37卷 / 02期
关键词：
D O I：
10.25259/NMJI_456_21
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Herpes zoster is a viral infection caused due to the reactivation of varicella-zoster virus that is localized to a single dermatome unilaterally. The factors responsible for its reactivation are increasing age, immunosuppressive drugs, malignancies, chronic liver and renal diseases. Herpes zoster was found to be one of the cutaneous manifestations of coronavirus disease 2019 (Covid-19). Various skin manifestations post- vaccination are being reported, which include injection site urticarial, maculopapular rash and positive dermographism. We report a patient of herpes zoster triggered by the viral vector (ChAdOx1 nCoV-19) coronavirus vaccine (recombinant).
引用
收藏
页码：89 / 90
页数：2
相关论文
共 50 条
  • [1] Herpes Zoster Following Vaccination with ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant)
    Job, Anupa Mary
    Sudhamani, Bindurani
    Mohan, Manju
    Mohanasundarama, S. N.
    INDIAN JOURNAL OF PUBLIC HEALTH, 2022, 66 (01) : 83 - 85
  • [2] Herpes zoster after ChAdOx1 nCoV-19 vaccine: a case series
    Vastarella, M.
    Picone, V.
    Martora, F.
    Fabbrocini, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (12) : E845 - E846
  • [3] Healthcare professionals & adverse events of ChAdOx1 nCoV-19 coronavirus vaccine Response
    Kaur, Sukhpal
    Singh, Ajay
    Saini, Sushma
    Rohilla, Latika
    Kaur, Jasvir
    Chandi, Anadeep
    Kaur, Gurpreet
    Singh, Manjeet
    Kumar, Pramod
    Soni, Shiv Lal
    Kajal, Kamal
    Naik, Naveen B.
    Malhotra, Pankaj
    Verma, Sanjay
    Gupta, Madhu
    Devnani, Mahesh
    Das, Karobi
    Pandav, S. S.
    Puri, G. D.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2022, 155 (5-6) : 591 - 592
  • [4] ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates
    McQuade, Elizabeth T. Rogawski
    Platts-Mills, James A.
    LANCET, 2021, 397 (10291): : 2247 - 2248
  • [5] Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine
    McQuade, Elizabeth T. Rogawski
    Breskin, Alexander
    LANCET, 2021, 398 (10304): : 933 - 935
  • [6] Fixed Drug Eruption after ChAdOx1 nCoV-19 Vaccine
    Jabri, F. E.
    Kastalli, S.
    Ferchichi, K.
    Dabbeche, S.
    Daghfous, R.
    Aidli, S. E.
    DRUG SAFETY, 2022, 45 (10) : 1197 - 1197
  • [7] Process-Related Impurities in the ChAdOx1 nCov-19 Vaccine
    Krutzke, Lea
    Roesler, Reinhild
    Allmendinger, Ellen
    Engler, Tatjana
    Wiese, Sebastian
    Kochanek, Stefan
    MOLECULAR THERAPY, 2022, 30 (04) : 342 - 342
  • [8] Cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine
    Abdulla, Mansoor C.
    INDIAN JOURNAL OF MEDICAL SPECIALITIES, 2022, 13 (04) : 263 - 264
  • [9] Emergence of COVID-19 variants among ChAdOx1 nCoV-19 (recombinant) vaccine recipients
    Vaishya, Raju
    Sibal, Anupam
    Singh, Sujeet Kumar
    Malani, Arpita
    Das, Shreya
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2021, 153 (05) : 559 - 561
  • [10] ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates reply
    Voysey, Merryn
    Pollard, Andrew J.
    LANCET, 2021, 397 (10291): : 2248 - 2248
12345